Immunome Inc

IMNM14 Dec 2024
Healthcare
$12.95
-0.04 (-3.67%)
Lowest Today
$12.35
Highest Today
$13.06
Today’s Open
$12.95
Prev. Close
$13.07
52 Week High
$30.96
52 Week Low
$7.01
To Invest in Immunome Inc

Immunome Inc

Healthcare
IMNM14 Dec 2024
-0.04 (-3.67%)
1M
3M
6M
1Y
5Y
Low
$12.35
Day’s Range
High
$13.06
12.35
52 Week Low
$7
52-Week Range
52 Week High
$30.96
7
1 Day
-
1 Week
-4.87%
1 month return
+12.75%
3 month return
-18.35%
6 month return
-18.4%
1 Year return
+77.95%
3 Years return
-21.86%
5 Years return
-
10 Years return
-
Institutional Holdings
T. Rowe Price Investment Management,Inc.
9.23
Redmile Group, LLC
7.83
FMR Inc
6.77
EcoR1 Capital, LLC
6.22
BlackRock Inc
6.02
HHG PLC
5.59
Vanguard Group Inc
5.02

Market Status

Fundamentals
Market Cap
876.33 mln
PB Ratio
4.08
PE Ratio
0
Enterprise Value
638.92 mln
Total Assets
148.54 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Organisation
Immunome Inc
Employees
55
Industry
Biotechnology
CEO
Dr. Clay B. Siegall Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities